摘要
HBV感染引起的慢性乙型肝炎是全球性的公共卫生问题,慢性HBV感染的抗病毒治疗是关键,抗病毒治疗的目标主要通过病毒学、血清学和生化学指标来定义。已批准上市的两大类抗病毒药物干扰素和核苷(酸)类似物均能减少肝脏炎症和纤维化以及降低肝硬化和肝细胞癌的发生率。然而,抗病毒治疗的理想目标是功能性治愈,其显著改善慢性乙型肝炎的远期结局。目前治疗方法的局限性在于抑制HBV复制,但不能清除病毒,HBeAg和HBsAg血清学清除率低。研发以功能性治愈为目标的新型药物,并评价与现有药物的协同、联合等作用是HBV治疗和发展的重要方向。
Chronic hepatitis B caused by hepatitis B virus(HBV)infection is a global public health issue.Antiviral therapy for chronic HBV infection plays a critical role,and the goal of antiviral therapy is mainly defined by virological,serological,and biochemical parameters.As the two types of antiviral drugs approved for marketing,both interferon and nucleos(t)ide analogues can alleviate liver inflammation and liver fibrosis and reduce the incidence rates of liver cirrhosis and hepatocellular carcinoma.However,the ideal goal of antiviral therapy is functional cure,which significantly improves the long-term outcome of chronic hepatitis B.The limitation of current treatment is that it can inhibit HBV replication,but cannot clear the virus,with low serological clearance rates of HBeAg and HBsAg.Development of new drugs with the goal of functional cure and evaluation of the synergistic and combined effects of existing drugs are important directions for HBV treatment and development.
作者
陈学福
张东敬
罗晓丹
陈仁
CHEN Xuefu;ZHANG Dongjing;LUO Xiaodan;CHEN Ren(Department of Infectious Diseases, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2021年第5期1011-1015,共5页
Journal of Clinical Hepatology
基金
广东省中医药局科研项目(20181007)。
